A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause

Hot Flashes Clinical Trial

— Moonlight 1  

Official title:

A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, Followed by a Non-Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women in Asia Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04234204
• Other study ID #: 2693-CL-0305
• Secondary ID: CTR20200360
• Status: Completed
• Phase: Phase 3
• Start date: March 17, 2020
• Est. completion date: April 20, 2022

Study information

• Verified date: September 2023
• Source: Astellas Pharma Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is for women in menopause with moderate to severe hot flashes. Menopause, a normal part of aging, is the time of a woman's last period. Hot flashes can interrupt a woman's daily life.

The study treatments are fezolinetant (1 tablet) once a day or placebo (1 tablet) once a day. (Placebo is a dummy treatment that looks like medicine but does not have any medicine in it.) The study will compare fezolinetant and placebo after 4 and 12 weeks of dosing. The study will see if fezolinetant reduces the number of hot flashes. And the study will see if fezolinetant reduces the severity of the hot flashes.

Women in the study will receive an electronic handheld device at the first study visit. (It is similar to a smart phone.) Each day of the study, study participants will use this to record their hot flashes. Their record for the 10 days before the start of study treatment will be checked. They can remain in the study if their record shows 7 or 8 moderate to severe hot flashes per day (50 or more per week).

Next, they will be picked for 1 of the 2 study treatments (fezolinetant or placebo) by chance alone. It is like flipping a coin.

The study participants will take study treatment for 24 weeks. The first 12 weeks of study treatment are "double-blinded." That means that the study participants and the study doctors do not know who takes which of the study treatments (fezolinetant or placebo) during that time. The last 12 weeks of study treatment are "noncontrolled." That means that each study participant and the study doctors know which study treatment that study participant takes during that time. Women who take fezolinetant during the first 12 weeks will continue to take fezolinetant. Women who take placebo during the first 12 weeks will start taking fezolinetant.

At weeks 2, 4, 8, 12, 14, 16, 20 and 24, the study participants will go to the hospital or clinic for a check-up. They will be asked about medications, side effects and how they feel. Other checks will include physical exam and vital signs (heart rate, temperature and blood pressure). Blood and urine will be collected for laboratory tests. Study participants will complete questionnaires that are about how hot flashes affect their daily life. Study participants who still have their uterus will have the following 2 tests done at the first and last study visits if they meet the criteria. One of the 2 tests is endometrial biopsy.

This test involves removing a small amount of tissue from the inside lining of the uterus. The tissue is then checked under a microscope. The other test is transvaginal ultrasound. This test uses sound waves to create pictures of the organs in the pelvis. The sound waves are transmitted by a probe (transducer), which is placed inside the vagina. Study participants may have a screening mammogram done at the first and/or last study visit. A mammogram is an x-ray picture of the breasts used to screen for breast cancer. Study participants who did not have this test done in the last 12 months will have it done at the first study visit. They will have it done at the last study visit if they are due for their screening mammogram and their own doctor agrees.

The last check-up at the hospital or clinic will be 3 weeks after the last dose of study treatment.

Description:

This study will consist of a screening period and a 24-week treatment period. Safety follow up will occur 3 weeks after the last dose of study drug.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 302
• Est. completion date: April 20, 2022
• Est. primary completion date: April 20, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 40 Years to 65 Years

Eligibility

Inclusion Criteria:

• Participant has a body mass index =16 kg/m^2 and =38 kg/m^2 (extremes included) at screening visit.

• Participant must be seeking treatment or relief for vasomotor symptoms (VMS) associated with menopause and confirmed as menopausal per 1 of the following criteria at the screening visit:

• Spontaneous amenorrhea for = 12 consecutive months

• Spontaneous amenorrhea for = 6 months with biochemical criteria of menopause (follicle stimulating hormone [FSH] > 40 IU/L); or

• Having had bilateral oophorectomy = 6 weeks prior to the screening visit (with or without hysterectomy)

• FSH > 40 IU/L if participants received hysterectomy but still have ovary

• Within the 10 days prior to randomization, participant must have a minimum average of 7 to 8 moderate to severe HFs (VMS) per day, or 50 to 60 per week.

• Participant is in good general health as determined on the basis of medical history and general physical examination, including a bimanual clinical pelvic examination and clinical breast examination devoid of relevant clinical findings, performed at the screening visit; hematology and biochemistry parameters, pulse rate and/or blood pressure, and electrocardiogram (ECG) within the reference range for the population studied, or showing no clinically relevant deviations.

• Participant has documentation of a normal/negative or no clinically significant findings mammogram (or echo) (e.g. < BI-RADS class 4; obtained at screening or within the prior 12 months of study enrollment). Appropriate documentation includes a written report or an electronic report indicating normal/negative or no clinically significant mammographic findings.

• Participant is willing to undergo a transvaginal ultrasound (TVU) to evaluate the uterus and ovaries at screening and week 24 (end-of-treatment), and for participants who are withdrawn from the study prior to completion, a TVU at the early discontinuation (ED) visit. This is not required for participants who have had a partial (supra-cervical) or full hysterectomy.

• Participant is willing to undergo an endometrial biopsy at screening, and at week 24 (end of treatment) or early discontinuation (ED) visit if endometrial thickness >4mm indicated by TVU; and participant is willing to undergo an endometrial biopsy at any time during the study in the case of uterine bleeding. This is not required for participants who have had a partial (supracervical) or full hysterectomy. A biopsy with insufficient material for evaluation, or unevaluable material, is acceptable provided the endometrial thickness is no greater than 8 mm.

• Participant has documentation of a normal or not clinically significant Pap test (or equivalent cervical cytology within the previous 12 months of study enrollment or at screening. This is not required for participants who have had a full hysterectomy.

• Participant has a negative urine pregnancy test at screening, this is not required for participants who have had a full hysterectomy.

• Participant has negative serology panel [i.e., negative hepatitis B surface antigen (HBsAg) and negative hepatitis C virus antibody (HCVAb) screens] at screening.

• Participant agrees not to participate in another interventional study while participating in the present study.

Exclusion Criteria:

• Participant uses a prohibited therapy (strong and moderate cytochrome P450 1A2 [CYP1A2] inhibitors, hormone replacement therapy [HRT], hormonal contraceptive or any treatment for VMS [prescription, over the counter, or herbal]) or is not willing to wash out and discontinue use of such drugs for the full duration of study conduct.

• Participant has known substance abuse or alcohol addiction within 6 months of screening.

• Participant has a history of a malignant tumor, except for non-metastatic basal cell carcinoma of the skin.

• Participant has uncontrolled hypertension, defined as systolic blood pressure = 140 mmHg or diastolic blood pressure as = 90 mmHg based on an average of 2 to 3 readings within the screening period. Participants with a medical history of hypertension who are well controlled may be enrolled. Participants who do not meet these criteria may, at the discretion of the investigator, be re-assessed after initiation or review of antihypertensive measures.

• Participant has a history of severe allergy, hypersensitivity, or intolerance to drugs in general, including the study drug and any of its excipients.

• For Participants with a uterus: Participant has an unacceptable result from the TVU assessment at screening, i.e. full length of endometrial cavity cannot be visualized or presence of a clinically significant finding.

• For Participants with a uterus and endometrial thickness >4mm indicated by TVU:

Participant has an endometrial biopsy confirming presence of disordered proliferative endometrium, endometrial hyperplasia, endometrial cancer, or other clinically significant at screening. A biopsy with insufficient material for evaluation, or unevaluable material is acceptable provided the endometrial thickness is no greater than 8 mm.

• Participant has a history within the last 6 months of undiagnosed uterine bleeding.

• Participant has a history of seizures or other convulsive disorders.

• Participant has a medical condition or chronic disease (including history of neurological [including cognitive], hepatic, renal, cardiovascular, gastrointestinal, pulmonary [e.g., moderate asthma], endocrine, or gynecological disease) or malignancy that could confound interpretation of the study outcome.

• Participant has active liver disease, jaundice, elevated liver aminotransferases (alanine aminotransferase [ALT] or aspartate aminotransferase [AST]), elevated total or direct bilirubin, elevated INR or elevated alkaline phosphatase (ALP). Patients with mildly elevated ALT or AST up to < 1.5 × the upper limit of normal (ULN) can be enrolled if total and direct bilirubin are normal. Patients with mildly elevated ALP (up to < 1.5 × ULN) can be enrolled if cholestatic liver disease is excluded and no cause other than fatty liver is diagnosed. Patients with Gilbert's syndrome with elevated total bilirubin may be enrolled as long as hemolysis is ruled out (i.e. direct bilirubin, hemoglobin and reticulocytes are normal).

• Participant has creatinine > 1.5 × ULN; or estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease formula = 59 mL/min/1.73 m^2 at screening.

• Participant has a positive result for human immunodeficiency virus (HIV) at screening.

• Participant has a history of suicide attempt or suicidal behavior within the last 12 months or has suicidal ideation within the last 12 months (a response of "yes" to question 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale [C-SSRS]), or who is at significant risk to commit suicide at screening and at visit 2.

• Participant has previously been enrolled in a clinical trial with fezolinetant.

• Participant has received investigational study drug within 28 days or 5 half-lives, whichever is longer, prior to screening.

• Participant is unable or unwilling to complete the study procedures.

• Participant has any condition which makes the subject unsuitable for study participation.

Related Conditions & MeSH terms

• Hot Flashes

Intervention

Drug:
• Fezolinetant
Oral
• Placebo
Oral

Locations

Country	Name	City	State
China	Site CN86001	Beijing
China	Site CN86002	Beijing
China	Site CN86017	Beijing
China	Site CN86030	Beijing
China	Site CN86022	Changchun
China	Site CN86009	Changsha
China	Site CN86037	Chengdu
China	Site CN86006	Guangzhou
China	Site CN86019	Guangzhou
China	Site CN86042	Guangzhou
China	Site CN86043	Guangzhou
China	Site CN86018	Guiyang
China	Site CN86025	Hangzhou
China	Site CN86034	Hangzhou
China	Site CN86027	Kunming
China	Site CN86005	Liuzhou
China	Site CN86004	Nanjing
China	Site CN86011	Nanjing
China	Site CN86035	Nanjing
China	Site CN86026	Nanning
China	Site CN86012	Shanghai
China	Site CN86021	Shenzhen
China	Site CN86007	Shijiazhuang
China	Site CN86023	Taiyuan
China	Site CN86031	Taiyuan
China	Site CN86015	Tianjin
China	Site CN86029	Tianjin
China	Site CN86008	Wuhan
China	Site CN86041	Yangzhou
China	Site CN86013	Yinchuan
China	Site CN86033	Zhongshan
Korea, Republic of	Site KR82013	Ansan-si
Korea, Republic of	Site KR82005	Busan
Korea, Republic of	Site KR82003	Seongnam-si
Korea, Republic of	Site KR82011	Seongnam-si
Korea, Republic of	Site KR82001	Seoul
Korea, Republic of	Site KR82002	Seoul
Korea, Republic of	Site KR82004	Seoul
Korea, Republic of	Site KR82006	Seoul
Korea, Republic of	Site KR82012	Seoul
Taiwan	Site TW88608	Kaohsiung City
Taiwan	Site TW88604	New Taipei City
Taiwan	Site TW88606	Taichung
Taiwan	Site TW88603	Tainan
Taiwan	Site TW88609	Tainan
Taiwan	Site TW88601	Taipei
Taiwan	Site TW88607	Taipei
Taiwan	Site TW88611	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Astellas Pharma China, Inc.

Countries where clinical trial is conducted

China,  Korea, Republic of,  Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean change from baseline in the frequency of moderate to severe vasomotor symptoms (VMS)	Frequency of moderate or severe VMS events will be calculated as the sum of moderate or severe VMS events per day.	Baseline to Week 4
Primary	Mean change from baseline in the frequency of moderate to severe VMS	Frequency of moderate or severe VMS events will be calculated as the sum of moderate or severe VMS events per day.	Baseline to Week 12
Primary	Mean change from baseline in the severity of moderate to severe VMS	The severity of VMS will be calculated using a weighted average of VMS events.	Baseline to Week 4
Primary	Mean change from baseline in the severity of moderate to severe VMS	The severity of VMS will be calculated using a weighted average of VMS events.	Baseline to Week 12
Secondary	Mean change from baseline to each week in the frequency of moderate and severe VMS	Frequency of moderate or severe VMS events will be calculated as the sum of moderate or severe VMS events per day.	Baseline to Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 11, 12
Secondary	Mean change from baseline to each week in the severity of moderate and severe VMS	The severity of VMS will be calculated using a weighted average of VMS events.	Baseline to Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 11, 12
Secondary	Mean percent reduction from baseline to each week in the frequency of moderate and severe VMS	Frequency of moderate or severe VMS events will be calculated as the sum of moderate or severe VMS events per day.	Baseline to Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 11, 12
Secondary	Percent reduction =50% from baseline to each week in the frequency of moderate and severe VMS	Frequency of moderate or severe VMS events will be calculated as the sum of moderate or severe VMS events per day. Ratio of the participants with =50% reduction in frequency will be reported.	Baseline to Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 11, 12
Secondary	Percent reduction at 100% from baseline to each week in the frequency of moderate and severe VMS	Frequency of moderate or severe VMS events will be calculated as the sum of moderate or severe VMS events per day. Ratio of the participants with = 100% reduction in frequency will be reported.	Baseline to Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 11, 12
Secondary	Mean change from baseline in the frequency of moderate to severe VMS	Frequency of moderate or severe VMS events will be calculated as the sum of moderate or severe VMS events per day.	Baseline to Week 24
Secondary	Mean change from baseline in the severity of moderate to severe VMS	The severity of VMS will be calculated using a weighted average of VMS events.	Baseline to Week 24
Secondary	Number of Participants With Adverse Events	An adverse event (AE) is any untoward medical occurrence in a participant administered a study drug, and which does not necessarily have to have a causal relationship with this treatment.	Up to 27 Weeks
Secondary	Number of Participants With Adverse Events Based on Severity	An AE is any untoward medical occurrence in a participant administered a study drug, and which does not necessarily have to have a causal relationship with this treatment.	Up to 27 Weeks
Secondary	Change From Baseline in Endometrial Thickness	Endometrial thickness is a measure of how thick the lining of the uterus is. Endometrial thickness will be measured by transvaginal ultrasound (TVU).	Baseline and Week 24
Secondary	Percentage of Participants With Endometrial Hyperplasia and/or Endometrial Cancer	Endometrial hyperplasia is thickening of the lining of the uterus. Endometrial cancer is cancer of the lining of the uterus.	Up to 24 Weeks
Secondary	Number of Participants With Vital Sign Abnormalities and/or Adverse Events	Number of participants with potentially clinically significant vital sign values will be reported.	Up to 27 Weeks
Secondary	Number of Participants With Electrocardiogram (ECG) Abnormalities and/or Adverse Events (AEs)	Number of participants with potentially clinically significant ECG values will be reported.	Up to 27 Weeks
Secondary	Number of Participants With Laboratory Value Abnormalities and/or Adverse Events (AEs)	Number of participants with potentially clinically significant laboratory values will be reported.	Up to 27 Weeks
Secondary	Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP)	Change from baseline in serum concentrations of BSAP will be reported.	Baseline, Week 24 and Week 27
Secondary	Change From Baseline in Procollagen Type 1 Aminoterminal Propeptide (P1NP)	Change from baseline in serum concentrations of P1NP will be reported.	Baseline, Week 24 and Week27
Secondary	Change From Baseline in Carboxy-Terminal Telopeptide of Type I Collagen (CTX)	Change from baseline in serum concentrations of CTX will be reported.	Baseline, Week 24 and Week 27
Secondary	Pharmacokinetics (PK) of Fezolinetant in Plasma: Concentration	Concentration will be recorded from the PK plasma samples collected.	Week 4, Week 12, Week 16, Week 24
Secondary	Pharmacokinetics (PK) of Fezolinetant Metabolite ES259564 in Plasma: Concentration	Concentration will be recorded from the PK plasma samples collected.	Week 4, Week 12, Week 16, Week 24
Secondary	Change from Baseline in Sex Hormones	Change from baseline in serum concentration of sex hormones will be reported.	Baseline, Week 4, Week 12, Week 24 and Week 27
Secondary	Change from Baseline in Sex Hormone-Binding Globulin (SHBG)	Change from baseline in serum concentration of SHBG will be reported.	Baseline, Week 4, Week 12, Week 24 and Week 27

External Links

•   Link Description: Link to plain language summary of the study on the Trial Results Summaries website.
•   Link Description: Link to results and other applicable study documents on the Astellas Clinical Trials website.